Related Experiment Video
Updated: Jan 19, 2026
10:04
Enhancing Tumor Content through Tumor Macrodissection
Published on: February 12, 2022
12.1K
Burkitt-like lymphoma with 11q aberration
Katrina Collins1, Laila Mnayer1, Peter Shen1
1Department of Pathology Hartford Hospital Hartford CT USA.
Clinical Case Reports
|September 20, 2019
Summary
Burkitt-like lymphoma with 11q aberration is a new WHO classification entity. Consider this diagnosis and perform cytogenetic array for high-grade B-cell lymphomas lacking MYC rearrangement.
Area of Science:
- Hematology
- Oncology
- Genetics
Background:
- The World Health Organization (WHO) classification of lymphoid neoplasms is periodically updated.
- Recent classifications recognize new entities based on molecular and genetic findings.
- High-grade B-cell lymphomas require precise diagnostic classification for appropriate management.
Purpose of the Study:
- To highlight Burkitt-like lymphoma with 11q aberration as a distinct diagnostic entity.
- To emphasize the importance of considering this entity in specific lymphoma cases.
- To recommend diagnostic approaches for identifying this lymphoma subtype.
Main Methods:
- Review of the latest WHO classification of lymphoid neoplasms.
- Analysis of diagnostic criteria for Burkitt-like lymphoma with 11q aberration.
- Guidance on appropriate cytogenetic testing for lymphoma diagnosis.
Main Results:
- Burkitt-like lymphoma with 11q aberration is a recognized entity in the WHO Revised 4th Edition.
- This lymphoma subtype is characterized by an 11q aberration.
- Absence of MYC rearrangement is a key feature in cases where this diagnosis should be considered.
Conclusions:
- Burkitt-like lymphoma with 11q aberration represents a significant addition to lymphoma classification.
- Cytogenetic array analysis is crucial for diagnosing lymphomas lacking MYC rearrangement.
- Accurate diagnosis of this entity aids in appropriate patient management and treatment strategies.
